Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer
Status:
Terminated
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as capecitabine, irinotecan, and oxaliplatin,
work in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill
more tumor cells. Monoclonal antibodies, such as bevacizumab, can block tumor growth in
different ways. Some find tumor cells and kill them or carry tumor-killing substances to
them. Others interfere with the ability of tumor cells to grow and spread. Bevacizumab may
also block blood flow to the tumor. Giving combination chemotherapy together with bevacizumab
may kill more tumor cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of capecitabine
when given together with irinotecan and oxaliplatin with or without bevacizumab and to see
how well they work in treating patients with metastatic or locally advanced colorectal cancer
or other solid tumors that cannot be removed by surgery.